These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 45343)

  • 1. [Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
    Bartholini G
    Schweiz Arch Neurol Neurochir Psychiatr; 1979; 125(2):265-9. PubMed ID: 45343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Implications of GABAergic synapses in neuropsychiatry].
    Lloyd KG; Perrault G; Zivkovic B
    J Pharmacol; 1985; 16 Suppl 2():5-27. PubMed ID: 2867252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the new gamma-aminobutyric acid agonist SL 76 002 on striatal acetylcholine: relation to neuroleptic-induced extrapyramidal alterations.
    Bartholini G; Scatton B; Zivkovic B
    Adv Biochem Psychopharmacol; 1980; 24():207-13. PubMed ID: 6105775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.
    Bartholini G; Scatton B; Zivkovic B; Lloyd KG
    Adv Neurol; 1987; 45():79-83. PubMed ID: 3030072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of GABA-mimetics in the therapy of extrapyramidal disorders.
    Bartholini G; Lloyd KG
    J Neural Transm Suppl; 1980; (16):229-38. PubMed ID: 6107332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuropathology of GABA neurons in extrapyramidal disorders.
    Lloyd KG
    J Neural Transm Suppl; 1980; (16):217-27. PubMed ID: 6448916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [GABA and diseases of the extrapyramidal system].
    Carrieri P
    Acta Neurol (Napoli); 1977; 32(5):697-704. PubMed ID: 22223
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of dopaminergic activity in the extrapyramidal and limbic systems by gamma-acetylenic GABA [proceedings].
    Huot S; Lippert B; Palfreyman MG; Schechter PJ
    Br J Pharmacol; 1977 Jun; 60(2):264P-265P. PubMed ID: 880435
    [No Abstract]   [Full Text] [Related]  

  • 11. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
    Lloyd KG; Worms P
    Adv Biochem Psychopharmacol; 1981; 29():59-67. PubMed ID: 6114626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABAergic control of substantia nigra dopaminergic neurons.
    Tepper JM; Lee CR
    Prog Brain Res; 2007; 160():189-208. PubMed ID: 17499115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABA receptor agonists: pharmacological spectrum and therapeutic actions.
    Bartholini G
    Med Res Rev; 1985; 5(1):55-75. PubMed ID: 2984490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotransmitter interactions related to central dopamine neurons.
    Lloyd KG
    Essays Neurochem Neuropharmacol; 1978; 3():129-207. PubMed ID: 30628
    [No Abstract]   [Full Text] [Related]  

  • 17. Functions of dopamine in the extrapyramidal and limbic systems. Clues for the mechanism of drug actions.
    Di Chiara G; Morelli M; Acquas E; Carboni E
    Arzneimittelforschung; 1992 Feb; 42(2A):231-7. PubMed ID: 1586394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of GABA.
    Meldrum B
    Clin Neuropharmacol; 1982; 5(3):293-316. PubMed ID: 6214305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic regulation of the GABAergic transmission in the rat basal ganglia.
    Di Cara B; Samuel D; Salin P; Kerkerian-Le Goff L; Daszuta A
    Synapse; 2003 Nov; 50(2):144-50. PubMed ID: 12923817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs.
    Fuxe K; Hökfelt T; Ljungdahl A; Agnati L; Johansson O; Perez de la Mora M
    Med Biol; 1975 Jun; 53(3):177-83. PubMed ID: 1160412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.